logo
Share SHARE
FONT-SIZE Plus   Neg

Repros Therapeutics To Meet With FDA To Discuss Phase 3 Study Design Of Androxal

Repros Therapeutics Inc.(RPRX: Quote) Monday said the FDA has scheduled a meeting in May to discuss the design of pivotal Phase 3 efficacy studies for Androxal, as well as the components of the overall drug development program required for NDA submission.

Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Unlike the hormone replacement therapies currently approved to treat this disorder, Androxal restores testicular function resulting in normal synthesis of testosterone and continued spermatogenesis.

Repros said studies using approved testosterone replacement therapies as efficacy and safety comparators have shown the approved treatments result in suppression of important pituitary hormones that drive testicular function down to castration levels in a significant number of men.

Joseph Podolski, president and CEO of The Woodlands, Texas-based company, said," Our goal is to work with the FDA to provide a complete drug dossier for Androxal that exhibits the products' clinical benefit and safety. Depending on FDA comments, we believe we can submit the NDA early in 2014."

RPRX closed Monday's regular trade at $4.35, down $0.15 or 3.33%, on the Nasdaq. In the after-hours, the stock gained $0.01 or 0.23%. Over the past year, the stock traded in a range of $3.34 - $6.85.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Fiat Chrysler Automobiles NV (FCAU) is recalling nearly 26 thousand Chrysler 200s to fix a transmission issue that may prevent the vehicle from shifting into "park." Chrysler said that certain 2015-model year Chrysler 200 vehicles with V6 engines were affected. Chrysler blamed "inconsistent assembly... Gap reported an increase in fourth-quarter profit, as same store sales climbed 11 percent at its Old Navy brand, partly offset by currency impact. Earnings for the quarter topped Wall Street estimates by a penny, while sales were in line with expectations. J.C. Penney Co. Inc. (JCP) Thursday reported a swing to loss in the fourth-quarter from a profit last year, reflecting the absence of benefits from hefty tax gains recorded last year, despite a higher-than-expected revenue growth. Shares of the struggling department store chain plunged a near 10 percent,...
comments powered by Disqus
Follow RTT